Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 March 2025 | Story Andre Damons | Photo Andre Damons
Dr Gerard Verhoef
Dr Gerard Verhoef, an intellectual property (IP) commercialisation specialist at Barnard Incorporated Attorneys, gave an oral presentation at the second Southern African Mountain Conference.

South Africa is neglecting and overlooking the economic potential of Aloe ferox, forfeiting millions in potential revenue from this ‘green gold’. In doing so, the country is denying farmers and communities the chance to prosper from the land’s true bounty and is also undermining its biodiversity.

While South Africa harvests a mere 200 tons of Aloe ferox annually, its global competitors, such as Mexico, churn out a staggering 400 000 tons of Aloe vera, says Dr Gerard Verhoef, an intellectual property (IP) commercialisation specialist at Barnard Incorporated Attorneys. He gave an oral presentation titled IKS, the public domain and Biotrade during a session on Mountain People's Livelihoods at the second Southern African Mountain Conference (SAMC2025).

Researchers, policy makers, and practitioners from across Southern Africa and beyond came together from 17 to 20 March at the scenic Champagne Sports Resort in the central Maluti-Drakensberg for SAMC2025 themed ‘Overcoming Boundaries and Barriers’.

The next rooibos

SAMC2025, under the patronage of UNESCO and organised by the University of the Free State (UFS) Afromontane Research Unit (ARU) – in partnership with the African Mountain Research Foundation (AMRF) and the Global Mountain Safeguard Research Programme (GLOMOS) – delved into critical issues around mountain ecosystems, communities, governance, and transboundary cooperation.

Aloe ferox could be the next rooibos, which is successfully using its geographical indications (GI) status to unlock value throughout the biotrade value chain, Dr Verhoef said. Other South African plants that are also an underutilised asset with economic potential for the country, include honeybush, baobab, umsuzwane, rose geranium, imphepho, Cape chamomile, Kalahari melon, mafura, sour plum, and African ginger.

A GI consists of the name of the place of origin. It links a product to a specific geographical area, which indicates the origin of where the product is produced, processed, or prepared.

Overlooking the potential of Aloe ferox, which has been scientifically proven to contain double the amino acids and 20 times more antioxidants than its international cousin, Aloe vera, Dr Verhoef explains, South Africa is not only undermining its biodiversity but also the economy. Aloe ferox is most popularly used for its laxative effect (aloe bitters) and as a topical application to the skin, eyes, and mucous membranes. It is also used for many traditional uses as well as cosmetic purposes.

Time to capitalise

According to him, Aloe ferox remains an underutilised asset, relegated to niche markets and small-scale production due to regulatory constraints and the unwillingness to obtain access and benefit-sharing (ABC) permits needed to navigate obstacles in South Africa as well as Namibia, Botswana, Zimbabwe, and Mozambique.

“This is not just an agricultural oversight; it is a glaring economic misstep. It is high time that South Africa capitalises on its green gold, turning the tables on international competitors and finally giving Aloe ferox the global podium it deserves. This is not just an agricultural oversight; it is a glaring economic misstep.

Aloe ferox could be a flagship in the global wellness market, much like rooibos has become for tea. But until we embrace and promote our indigenous resources with the same vigour as we do foreign ones, our ‘green gold’ will remain just out of reach, a latent promise unfulfilled. It’s high time South Africa capitalise and turn the tables on international competitors, finally giving Aloe ferox the global podium it deserves,” said Dr Verhoef.

The path forward, he explains, requires a radical shift in how we view and value our native species. It demands a coalition of dedicated scientists, legal advisers, and farmers to advocate for more accommodating regulations and stronger market support. The pharmaceutical and cosmetic industries – major users of aloe products – must also be brought into the fold to help recalibrate the scales in favour of Aloe ferox. South Africa’s rich biodiversity is a national treasure, yet our approach to leveraging this wealth remains timid and fragmented.

News Archive

DNA sequencer launched at the UFS
2013-11-25

Dr Gansen Pillay, Deputy Chief Executive Officer of the National Research Foundation, explaining to the scholars what will be expected of them.

The University of the Free State (UFS) can now collect immensely valuable data on drug resistance in HIV/Aids and TB with the new DNA sequencer that was launched recently at the International workshop on HIV/AIDS and TB drug resistance at the Bloemfontein Campus.

The DNA sequencer will allow the Free State province to produce viral and bacterial genetic data to fight the local development of HIV/ Aids and TB drug resistance.

The HIV and TB epidemics have expanded very fast and South Africa now has the largest HIV and TB treatment programme in the world, with over 2 million patients on treatment. However, these successful treatment programmes are now being threatened by the appearance of drug resistance.

The Free State province has been at the forefront of fighting HIV drug resistance in South Africa and has one of the most advanced treatment programmes for the management of resistance strains in the country. In addition, researchers at the University of the Free State are leading partners in the Southern African Treatment and Resistance Network (SATuRN; www.bioafrica.net/saturn), a research network that has trained over 2 000 medical officers in the treatment of drug resistance strains.

The Department of Medical Microbiology and Virology in the Medical School at the UFS has partnered with the provincial department of health, the Medical Research Council (MRC) and the Delegation of the European Union to South Africa to fund a dedicated DNA sequencer machine that will be used to generate HIV and TB drug-resistance results. This new machine will enable cutting-edge research to take place, using the data in the province and, importantly, support patients with resistance strains to have access to advanced genotypic testing techniques.

“HIV drug resistance is a very serious problem in South Africa, and the recent advances in DNA testing technology allow clinicians in the province to access drug resistance testing, which enables them to manage patients appropriately who fail treatment, and use the results to cost-effectively extend and improve patients’ lives,” says Dr Cloete van Vuuren, Specialist in Infectious Diseases at the UFS’s Faculty of Health.

Dr Dominique Goedhals, pathologist from the Department of Medical Microbiology and Virology at the UFS, adds: “We have been looking forward to expanding our work with the clinicians and researchers, using DNA sequencing to shed light on the causes and consequences of drug resistance in urban and rural settings in the province.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept